case_images: PMC5339529_01
case_images: Bone marrow aspirate, biopsy, metaphases cytogenetic, and response to Dasatinib in a Ph+ LR-MDS patient. (a) Erythroid precursor with nuclear irregularity, budding, and nuclear/cytoplasm desynchronization. (b) Dysplastic erythroid precursors with karyorrhexis. (c) shows hypolobated dysplastic megakaryocytes. (d) Patient karyotype showing t (9; 22) translocation. (e) Progressive increase in hemoglobin level for a Ph + LR-MDS [RCMD] patient treated with low-dose Dasatinib. Progressive H-E was observed at 12 weeks. HI-E was sustained at 24 weeks of treatment.
case_images: CRIHEM2017-5404131.001.jpg
case_images: PMC5339529_01_CRIHEM2017-5404131.001.jpg
case_images: fig1
case_images: His erythroid cells showed nuclear irregularities, budding, and nuclear/cytoplasmic desynchronization (Figures 1(a) and 1(b)). Micromegakaryocytes were hypolobated (Figure 1(c)). Karyotype was 46, XY, t (9:22) [4], XY [16] (Figure 1(d)). His hemoglobin progressively increased by 3 g/dL after 12 weeks of treatment (Figure 1(e)). Response was maintained for a total of 24 weeks (Figure 1(e)).